Literature DB >> 19146797

Hypertension in women.

Sandra J Taler1.   

Abstract

Systolic blood pressure is higher in African American and Hispanic women older than 60 and in white women older than 70 than it is in men. Coupled with their longer survival, elderly women have higher hypertension prevalence rates, particularly for isolated systolic hypertension. Hemodynamic characteristics differ by sex for premenopausal women and age-matched men, but these differences lessen after menopause. This transition may result from hormonal or metabolic alterations, including weight gain and tissue adiposity, which are common after menopause. Clinical trials enrolling large numbers of women support the benefits of treatment to reduce cardiovascular events and mortality. The trend to enroll subjects with several comorbidities and thereby increase event rates may limit the applicability of trial results to healthier women. Women appear more prone to develop side effects from antihypertensive medications and may metabolize these agents differently. There is a need for additional studies regarding appropriate drug selection, dosage, and combination therapy for women.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19146797     DOI: 10.1007/s11906-009-0006-9

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  32 in total

1.  Efficacy of treating hypertension in women.

Authors:  A Quan; K Kerlikowske; F Gueyffier; J P Boissel
Journal:  J Gen Intern Med       Date:  1999-12       Impact factor: 5.128

2.  Females in clinical studies: where are we going?

Authors:  K Uhl; A Parekh; S Kweder
Journal:  Clin Pharmacol Ther       Date:  2007-02-21       Impact factor: 6.875

Review 3.  Oral contraceptives and hypertension.

Authors:  J W Woods
Journal:  Hypertension       Date:  1988-03       Impact factor: 10.190

4.  Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators.

Authors:  F Gueyffier; F Boutitie; J P Boissel; S Pocock; J Coope; J Cutler; T Ekbom; R Fagard; L Friedman; M Perry; R Prineas; E Schron
Journal:  Ann Intern Med       Date:  1997-05-15       Impact factor: 25.391

5.  Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.

Authors:  Henry R Black; William J Elliott; Gregory Grandits; Patricia Grambsch; Tracy Lucente; William B White; James D Neaton; Richard H Grimm; Lennart Hansson; Yves Lacourciere; James Muller; Peter Sleight; Michael A Weber; Gordon Williams; Janet Wittes; Alberto Zanchetti; Robert J Anders
Journal:  JAMA       Date:  2003 Apr 23-30       Impact factor: 56.272

6.  Prospective study of oral contraceptives and hypertension among women in the United States.

Authors:  L Chasan-Taber; W C Willett; J E Manson; D Spiegelman; D J Hunter; G Curhan; G A Colditz; M J Stampfer
Journal:  Circulation       Date:  1996-08-01       Impact factor: 29.690

7.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

8.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

9.  Feasibility of treating prehypertension with an angiotensin-receptor blocker.

Authors:  Stevo Julius; Shawna D Nesbitt; Brent M Egan; Michael A Weber; Eric L Michelson; Niko Kaciroti; Henry R Black; Richard H Grimm; Franz H Messerli; Suzanne Oparil; M Anthony Schork
Journal:  N Engl J Med       Date:  2006-03-14       Impact factor: 91.245

10.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors:  Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

View more
  3 in total

Review 1.  STIM and Orai proteins: players in sexual differences in hypertension-associated vascular dysfunction?

Authors:  Fernanda R C Giachini; R Clinton Webb; Rita C Tostes
Journal:  Clin Sci (Lond)       Date:  2009-12-15       Impact factor: 6.124

2.  Childhood social class and adult adiposity and blood-pressure trajectories 36-53 years: gender-specific results from a British birth cohort.

Authors:  Bjørn Heine Strand; Emily T Murray; Jack Guralnik; Rebecca Hardy; Diana Kuh
Journal:  J Epidemiol Community Health       Date:  2010-11-23       Impact factor: 3.710

Review 3.  Hypertension criterion for stroke prevention--to strengthen the principle of individualization in guidelines.

Authors:  Yicong Chen; Xinran Chen; Ge Dang; Yuhui Zhao; Fubing Ouyang; Zhenpei Su; Jinsheng Zeng
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-01-05       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.